Baidu
map

Spine:BMP临床试验数据共享是科学进步的开端

2014-04-18 佚名 丁香园

始于2011年关于人重组骨形态发生蛋白2(rhBMP-2)的争论,不仅提出了rhBMP-2临床应用的安全性问题,也关注到循证医学建立过程中的重要缺点。目前,近一半的临床试验结果未得以发表;发表的临床试验往往忽略了重要的数据,而且发表的延误期长;其中关于患者个体的数据未公布以便进行再分析。 另一方面,临床研究中的经济利益也使得研究的执行和发布产生偏差。2011年Spine J上的一系列支持rh

始于2011年关于人重组骨形态发生蛋白2(rhBMP-2)的争论,不仅提出了rhBMP-2临床应用的安全性问题,也关注到循证医学建立过程中的重要缺点。目前,近一半的临床试验结果未得以发表;发表的临床试验往往忽略了重要的数据,而且发表的延误期长;其中关于患者个体的数据未公布以便进行再分析。

另一方面,临床研究中的经济利益也使得研究的执行和发布产生偏差。2011年Spine J上的一系列支持rhBMP-2的文章,这些文章的研究者们有明显的经济利益关系。这些厂家赞助的研究可能未完全报道重要的副作用,这些研究中上述重要的缺点均存在。

美国耶鲁大学医学院的学者,就rhBMP-2临床试验的开放科学和数据共享进行了述评,评价其为科学进步的开端,文章于2014年4月发表在Spine上。

为解决临床试验中存在的问题,rhBMP-2的生产者—美敦力公司提出了耶鲁大学开发数据获取(YODA)项目,该项目中研究数据及管理均透明,以便阐明rhBMP-2的有效性和安全性。

具体而言,该项目通过开放竞标,选择了在荟萃分析和病例数据整理方面专业性高的两所大学,对美敦力之前进行过的所有临床试验和病例资料,进行独立的系统回顾研究。选定的大学是俄勒冈健康与科学大学和约克大学。

尽管两所大学所用的方法不尽相同,但总体而言,结果类似。在脊柱融合方面,rhBMP-2略优于髂骨移植,但考虑到不同的手术入路因素,该优越性几乎不存在。无论前路腰椎椎间融合还是后外侧融合,rhBMP-2与髂骨在临床疗效和并发症方面无明显差别。唯一不同的是髂骨移植带来的术后短期疼痛。

rhBMP-2可致颈前路手术并发症发生率增高;术后2年可致患者肿瘤发生率轻度增高,术后4年此差别消失。肿瘤的绝对风险性较低,且肿瘤为多种因素所致。

YODA项目中所有临床试验数据的公布,为开放科学的范例。目前,欧洲监管机构—欧洲药品管理局正在完成制定这样的规范,使得申请临床试验的临床研究数据开放。美国药品研究与生产者及欧洲药品工业协会联盟,均承诺发布更多的临床试验数据。

通过公布rhBMP-2所有的厂家数据,包括之前未发表及关于副作用的详细报告,医生和患者均能对该产品的优点和缺点有完整深入的认识。这些开放科学和数据分享的努力,希望成为科学进步的开端。

原始出处:


Low JB1, Ross JS, Krumholz HM.Moving Forward From rhBMP-2: Open Science and Data Sharing.Spine (Phila Pa 1976). 2014 Apr 1;39(7):531-2. doi: 10.1097/BRS.0000000000000256.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1633997, encodeId=a21d163399efd, content=<a href='/topic/show?id=596635e549' target=_blank style='color:#2F92EE;'>#BMP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3575, encryptionId=596635e549, topicName=BMP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d95322064897, createdName=HNYYM, createdTime=Fri Jan 16 08:13:00 CST 2015, time=2015-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055224, encodeId=b84a205522445, content=<a href='/topic/show?id=6f9391e7414' target=_blank style='color:#2F92EE;'>#试验数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91774, encryptionId=6f9391e7414, topicName=试验数据)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Mon Jul 14 03:13:00 CST 2014, time=2014-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1699294, encodeId=57701699294ee, content=<a href='/topic/show?id=f5821661e14' target=_blank style='color:#2F92EE;'>#Spine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16617, encryptionId=f5821661e14, topicName=Spine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba5829925263, createdName=mgqwxj, createdTime=Thu Apr 24 22:13:00 CST 2014, time=2014-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1591245, encodeId=5d2815912455b, content=<a href='/topic/show?id=436d299e33d' target=_blank style='color:#2F92EE;'>#共享#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29973, encryptionId=436d299e33d, topicName=共享)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ec1e17938205, createdName=chendoc248, createdTime=Sun Apr 20 01:13:00 CST 2014, time=2014-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593832, encodeId=fb5f159383274, content=<a href='/topic/show?id=a8585e72779' target=_blank style='color:#2F92EE;'>#数据共享#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57727, encryptionId=a8585e72779, topicName=数据共享)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c28e18169649, createdName=dinorsor530, createdTime=Sun Apr 20 01:13:00 CST 2014, time=2014-04-20, status=1, ipAttribution=)]
    2015-01-16 HNYYM
  2. [GetPortalCommentsPageByObjectIdResponse(id=1633997, encodeId=a21d163399efd, content=<a href='/topic/show?id=596635e549' target=_blank style='color:#2F92EE;'>#BMP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3575, encryptionId=596635e549, topicName=BMP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d95322064897, createdName=HNYYM, createdTime=Fri Jan 16 08:13:00 CST 2015, time=2015-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055224, encodeId=b84a205522445, content=<a href='/topic/show?id=6f9391e7414' target=_blank style='color:#2F92EE;'>#试验数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91774, encryptionId=6f9391e7414, topicName=试验数据)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Mon Jul 14 03:13:00 CST 2014, time=2014-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1699294, encodeId=57701699294ee, content=<a href='/topic/show?id=f5821661e14' target=_blank style='color:#2F92EE;'>#Spine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16617, encryptionId=f5821661e14, topicName=Spine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba5829925263, createdName=mgqwxj, createdTime=Thu Apr 24 22:13:00 CST 2014, time=2014-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1591245, encodeId=5d2815912455b, content=<a href='/topic/show?id=436d299e33d' target=_blank style='color:#2F92EE;'>#共享#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29973, encryptionId=436d299e33d, topicName=共享)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ec1e17938205, createdName=chendoc248, createdTime=Sun Apr 20 01:13:00 CST 2014, time=2014-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593832, encodeId=fb5f159383274, content=<a href='/topic/show?id=a8585e72779' target=_blank style='color:#2F92EE;'>#数据共享#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57727, encryptionId=a8585e72779, topicName=数据共享)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c28e18169649, createdName=dinorsor530, createdTime=Sun Apr 20 01:13:00 CST 2014, time=2014-04-20, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1633997, encodeId=a21d163399efd, content=<a href='/topic/show?id=596635e549' target=_blank style='color:#2F92EE;'>#BMP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3575, encryptionId=596635e549, topicName=BMP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d95322064897, createdName=HNYYM, createdTime=Fri Jan 16 08:13:00 CST 2015, time=2015-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055224, encodeId=b84a205522445, content=<a href='/topic/show?id=6f9391e7414' target=_blank style='color:#2F92EE;'>#试验数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91774, encryptionId=6f9391e7414, topicName=试验数据)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Mon Jul 14 03:13:00 CST 2014, time=2014-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1699294, encodeId=57701699294ee, content=<a href='/topic/show?id=f5821661e14' target=_blank style='color:#2F92EE;'>#Spine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16617, encryptionId=f5821661e14, topicName=Spine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba5829925263, createdName=mgqwxj, createdTime=Thu Apr 24 22:13:00 CST 2014, time=2014-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1591245, encodeId=5d2815912455b, content=<a href='/topic/show?id=436d299e33d' target=_blank style='color:#2F92EE;'>#共享#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29973, encryptionId=436d299e33d, topicName=共享)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ec1e17938205, createdName=chendoc248, createdTime=Sun Apr 20 01:13:00 CST 2014, time=2014-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593832, encodeId=fb5f159383274, content=<a href='/topic/show?id=a8585e72779' target=_blank style='color:#2F92EE;'>#数据共享#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57727, encryptionId=a8585e72779, topicName=数据共享)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c28e18169649, createdName=dinorsor530, createdTime=Sun Apr 20 01:13:00 CST 2014, time=2014-04-20, status=1, ipAttribution=)]
    2014-04-24 mgqwxj
  4. [GetPortalCommentsPageByObjectIdResponse(id=1633997, encodeId=a21d163399efd, content=<a href='/topic/show?id=596635e549' target=_blank style='color:#2F92EE;'>#BMP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3575, encryptionId=596635e549, topicName=BMP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d95322064897, createdName=HNYYM, createdTime=Fri Jan 16 08:13:00 CST 2015, time=2015-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055224, encodeId=b84a205522445, content=<a href='/topic/show?id=6f9391e7414' target=_blank style='color:#2F92EE;'>#试验数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91774, encryptionId=6f9391e7414, topicName=试验数据)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Mon Jul 14 03:13:00 CST 2014, time=2014-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1699294, encodeId=57701699294ee, content=<a href='/topic/show?id=f5821661e14' target=_blank style='color:#2F92EE;'>#Spine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16617, encryptionId=f5821661e14, topicName=Spine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba5829925263, createdName=mgqwxj, createdTime=Thu Apr 24 22:13:00 CST 2014, time=2014-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1591245, encodeId=5d2815912455b, content=<a href='/topic/show?id=436d299e33d' target=_blank style='color:#2F92EE;'>#共享#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29973, encryptionId=436d299e33d, topicName=共享)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ec1e17938205, createdName=chendoc248, createdTime=Sun Apr 20 01:13:00 CST 2014, time=2014-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593832, encodeId=fb5f159383274, content=<a href='/topic/show?id=a8585e72779' target=_blank style='color:#2F92EE;'>#数据共享#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57727, encryptionId=a8585e72779, topicName=数据共享)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c28e18169649, createdName=dinorsor530, createdTime=Sun Apr 20 01:13:00 CST 2014, time=2014-04-20, status=1, ipAttribution=)]
    2014-04-20 chendoc248
  5. [GetPortalCommentsPageByObjectIdResponse(id=1633997, encodeId=a21d163399efd, content=<a href='/topic/show?id=596635e549' target=_blank style='color:#2F92EE;'>#BMP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3575, encryptionId=596635e549, topicName=BMP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d95322064897, createdName=HNYYM, createdTime=Fri Jan 16 08:13:00 CST 2015, time=2015-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055224, encodeId=b84a205522445, content=<a href='/topic/show?id=6f9391e7414' target=_blank style='color:#2F92EE;'>#试验数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91774, encryptionId=6f9391e7414, topicName=试验数据)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Mon Jul 14 03:13:00 CST 2014, time=2014-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1699294, encodeId=57701699294ee, content=<a href='/topic/show?id=f5821661e14' target=_blank style='color:#2F92EE;'>#Spine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16617, encryptionId=f5821661e14, topicName=Spine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba5829925263, createdName=mgqwxj, createdTime=Thu Apr 24 22:13:00 CST 2014, time=2014-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1591245, encodeId=5d2815912455b, content=<a href='/topic/show?id=436d299e33d' target=_blank style='color:#2F92EE;'>#共享#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29973, encryptionId=436d299e33d, topicName=共享)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ec1e17938205, createdName=chendoc248, createdTime=Sun Apr 20 01:13:00 CST 2014, time=2014-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593832, encodeId=fb5f159383274, content=<a href='/topic/show?id=a8585e72779' target=_blank style='color:#2F92EE;'>#数据共享#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57727, encryptionId=a8585e72779, topicName=数据共享)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c28e18169649, createdName=dinorsor530, createdTime=Sun Apr 20 01:13:00 CST 2014, time=2014-04-20, status=1, ipAttribution=)]

相关资讯

美敦力宣布8.16亿美元收购康辉医疗

   2012年9月28日—美敦力公司(纽约证交所:MDT)和康辉控股(中国)公司(纽约证交所:KH)今天宣布,双方已经订立了一项合并协议,据此美敦力将并购康辉。这一协议需要美敦力向康辉支付大约8.16亿美元的现金(30.75美元每美国储存股)。扣除康辉的现金,该交易的总价值为大约7.55亿美元。美敦力此次收购,溢价38%全资收购康辉医疗。这可是个大消息,看来国内的骨科植入器械

FDA批准美敦力CRT-ICD设备用于轻度心脏衰竭的治疗

2012年4月10日,美敦力(Medtronic)公司周二宣布,其心脏治疗设备已获FDA批准扩大适应症,用于轻度心脏衰竭患者的治疗。 此前,该心脏再同步化治疗(CRT)与植入式心律转复除颤器(ICD)设备(cardiac resynchronization therapy with implantable cardioverter defibrillator devices)仅被批准用于中度至重

美敦力新一代胸主动脉覆膜支架Capitivia获批准

 MedSci评论:  支架的发展史是相当值得思考的。早期的裸金属支架,只是暂时“撑开”血管,结果一系列的后遗症就会出现,如早期血栓,再闭塞等等。于是人们想到药物洗脱支架(DES),防止再闭塞,但是晚期血栓又难以避免,因为暴露在外的支架,始终无法做到象原生的“内皮”那样光滑。因此,新一代覆膜支架应运而生,但相信“覆膜”还无法解决一切问题,未来的支架不仅仅是撑开血管,还应该

FDA扩美敦力CRT适应证

近日,美国食品与药物管理局(FDA)批准了10种美敦力双心室起搏器用于治疗伴有不太严重收缩期心衰和需右室置入起搏器的房室传导阻滞患者。 CRT-D和CRT-P既往仅被批准用于LVEF<35%且QRS间期延长的心衰患者。此次适应证扩展主要基于BLOCK-HF随机试验结果而做出。BLOCK-HF试验共纳入691例伴有一度、二度或三度房室传导阻滞、NYHA分级1~3心衰和LVEF<50%的

美敦力2亿美元收购疾病管理与患者监护服务提供商Cardiocom

        2013年8月12日 ,世界最大医疗设备制造商美敦力公司(MDT)周一宣布,已同意以2亿美元收购疾病管理与患者监护服务提供商Cardiocom LLC。   美敦力表示,预计此项收购不会对其2014财年盈利产生影响。该公司表示,此项收购是其扩大对健康护理行业产品供应的计划之一部分。   Cardiocom专注于糖

Baidu
map
Baidu
map
Baidu
map